TEXT-Fitch comments on Bristol Myers Squibb's acquisition of Inhibitex
January 11, 2012 at 09:31 AM EST
Jan 11 - Fitch Ratings believes that Bristol-Myers Squibb Co.'s (Bristol Myers Squibb) purchase of Inhibitex, Inc. (Inhibitex) for approximately $2.5 billion is consistent with the current rating rationale for the company. Fitch rates Bristol Myers Squibb's as follows:
